Mephenytoin

DB00532

small molecule approved investigational withdrawn

Deskripsi

Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incidences of blood dyscrasias compared to other anticonvulsants.

Struktur Molekul 2D

Berat 218.2518
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Approximately 7 hours
Volume Distribusi * 1.4 L/kg
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Farmakogenomik

3 Varian
CYP2C19 (rs4986893)

Patients with this genotype have reduced metabolism of mephenytoin.

CYP2C19 (rs41291556)

Patients with this genotype have reduced metabolism of mephenytoin.

CYP2C19 (rs72558186)

Patients with this genotype have reduced metabolism of mephenytoin.

Interaksi Obat

1454 Data
Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Mephenytoin.
Deferasirox The serum concentration of Mephenytoin can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Mephenytoin can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Mephenytoin can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Mephenytoin can be decreased when it is combined with Teriflunomide.
Buprenorphine Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Hydrocodone Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Magnesium sulfate The therapeutic efficacy of Mephenytoin can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Mephenytoin may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Mirtazapine Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Orphenadrine Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Pramipexole Mephenytoin may increase the sedative activities of Pramipexole.
Ropinirole Mephenytoin may increase the sedative activities of Ropinirole.
Rotigotine Mephenytoin may increase the sedative activities of Rotigotine.
Sodium oxybate Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Thalidomide Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Mefloquine The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mefloquine.
Mianserin The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mianserin.
Orlistat Orlistat can cause a decrease in the absorption of Mephenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy.
Metyrapone The serum concentration of Metyrapone can be decreased when it is combined with Mephenytoin.
Rufinamide The serum concentration of Mephenytoin can be increased when it is combined with Rufinamide.
Topotecan Mephenytoin may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Mephenytoin.
Mifepristone The serum concentration of Mephenytoin can be increased when it is combined with Mifepristone.
Tetracosactide The risk or severity of liver damage can be increased when Tetracosactide is combined with Mephenytoin.
Mirabegron The serum concentration of Mephenytoin can be increased when it is combined with Mirabegron.
Eslicarbazepine acetate The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Mephenytoin.
Eslicarbazepine The serum concentration of Eslicarbazepine can be decreased when it is combined with Mephenytoin.
Abiraterone The serum concentration of Mephenytoin can be increased when it is combined with Abiraterone.
Cyproterone acetate The metabolism of Mephenytoin can be increased when combined with Cyproterone acetate.
Ethanol Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Mephenytoin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Mephenytoin.
Sibutramine The risk or severity of adverse effects can be increased when Mephenytoin is combined with Sibutramine.
Zimelidine The risk or severity of adverse effects can be increased when Mephenytoin is combined with Zimelidine.
Milnacipran The risk or severity of adverse effects can be increased when Mephenytoin is combined with Milnacipran.
Seproxetine The risk or severity of adverse effects can be increased when Mephenytoin is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Mephenytoin is combined with Indalpine.
Alaproclate The risk or severity of adverse effects can be increased when Mephenytoin is combined with Alaproclate.
Trazodone The risk or severity of adverse effects can be increased when Mephenytoin is combined with Trazodone.
Sertraline The risk or severity of adverse effects can be increased when Mephenytoin is combined with Sertraline.
Nefazodone The risk or severity of adverse effects can be increased when Mephenytoin is combined with Nefazodone.
Dapoxetine The risk or severity of adverse effects can be increased when Mephenytoin is combined with Dapoxetine.
Desvenlafaxine The serum concentration of Mephenytoin can be increased when it is combined with Desvenlafaxine.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Mephenytoin.
Propiomazine The risk or severity of CNS depression can be increased when Mephenytoin is combined with Propiomazine.
Pizotifen The risk or severity of CNS depression can be increased when Mephenytoin is combined with Pizotifen.
Trospium The metabolism of Mephenytoin can be decreased when combined with Trospium.
Benzatropine The metabolism of Mephenytoin can be decreased when combined with Benzatropine.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Mephenytoin.
Promazine The risk or severity of CNS depression can be increased when Promazine is combined with Mephenytoin.
Biperiden The metabolism of Mephenytoin can be decreased when combined with Biperiden.
Cocaine The risk or severity of methemoglobinemia can be increased when Mephenytoin is combined with Cocaine.
Maprotiline The risk or severity of CNS depression can be increased when Mephenytoin is combined with Maprotiline.
Tolterodine The metabolism of Tolterodine can be decreased when combined with Mephenytoin.
Oxybutynin The metabolism of Mephenytoin can be decreased when combined with Oxybutynin.
Promethazine The risk or severity of CNS depression can be increased when Mephenytoin is combined with Promethazine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Mephenytoin is combined with Diphenhydramine.
Doxepin The risk or severity of CNS depression can be increased when Mephenytoin is combined with Doxepin.
Quetiapine The risk or severity of CNS depression can be increased when Mephenytoin is combined with Quetiapine.
Aripiprazole The risk or severity of CNS depression can be increased when Mephenytoin is combined with Aripiprazole.
Tiotropium The metabolism of Tiotropium can be decreased when combined with Mephenytoin.
Solifenacin The metabolism of Solifenacin can be decreased when combined with Mephenytoin.
Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Mephenytoin.
Umeclidinium The metabolism of Umeclidinium can be decreased when combined with Mephenytoin.
Revefenacin The metabolism of Revefenacin can be decreased when combined with Mephenytoin.
Zopiclone The risk or severity of adverse effects can be increased when Mephenytoin is combined with Zopiclone.
Rifampin The metabolism of Mephenytoin can be increased when combined with Rifampicin.
Primidone The metabolism of Mephenytoin can be increased when combined with Primidone.
Albendazole The metabolism of Mephenytoin can be increased when combined with Albendazole.
Caffeine The metabolism of Mephenytoin can be decreased when combined with Caffeine.
Moxifloxacin The metabolism of Mephenytoin can be decreased when combined with Moxifloxacin.
Lidocaine The risk or severity of methemoglobinemia can be increased when Mephenytoin is combined with Lidocaine.
Mexiletine The metabolism of Mephenytoin can be decreased when combined with Mexiletine.
Gatifloxacin The metabolism of Mephenytoin can be decreased when combined with Gatifloxacin.
Simeprevir The metabolism of Mephenytoin can be decreased when combined with Simeprevir.
Lobeglitazone The metabolism of Mephenytoin can be decreased when combined with Lobeglitazone.
Pazufloxacin The metabolism of Mephenytoin can be decreased when combined with Pazufloxacin.
Osilodrostat The metabolism of Mephenytoin can be decreased when combined with Osilodrostat.
Imipramine The metabolism of Mephenytoin can be decreased when combined with Imipramine.
Desipramine The metabolism of Mephenytoin can be decreased when combined with Desipramine.
Dosulepin The metabolism of Mephenytoin can be decreased when combined with Dosulepin.
Cyclosporine The metabolism of Mephenytoin can be decreased when combined with Cyclosporine.
Cimetidine The metabolism of Mephenytoin can be decreased when combined with Cimetidine.
Ketoconazole The metabolism of Mephenytoin can be decreased when combined with Ketoconazole.
Sulfaphenazole The metabolism of Mephenytoin can be decreased when combined with Sulfaphenazole.
Manidipine The metabolism of Mephenytoin can be decreased when combined with Manidipine.
Cholecalciferol The metabolism of Mephenytoin can be decreased when combined with Cholecalciferol.

Target Protein

Sodium channel protein type 5 subunit alpha SCN5A
Nuclear receptor subfamily 1 group I member 2 NR1I2

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 1 • International brands: 0
Produk
  • Mesantoin
    Tablet • 100 mg/1 • Oral • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul